As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the ...

Chinese biotechs are increasingly seeking deals with multinational companies, and those deal structures are getting more creative. The “newco” deal structure is getting a lot of attention, but the ...

When the U.S. CDC and FDA recently removed several webpages and datasets from their websites in compliance with a directive from the Office of Personnel Management, they broke the law and harmed ...

Newco Akribion Therapeutics GmbH has raised €8 million (US$8.3 million) in a seed round to develop a new and potent class of RNA-targeted CRISPR nucleases, which, rather than cleaving specific nucleic ...

HCW Biologics Inc. has received clearance of its IND application from the FDA to initiate a first-in-human phase I trial to ...

Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...

Researchers from Shenzhen University have evaluated the potential antiallergic effects of the histone acetyltransferase KAT6A inhibitor WM-1119 on IgE-mediated mast cell activation and allergic ...

Japan’s drug pricing scheme has gotten more complicated, and pharma companies should brace themselves for annual price cuts.

University of California has described tropane derivatives acting as 5-HT2 and muscarinic receptor ligands reported to be useful for the treatment of psychiatric disorders, depression, ...

One potentially serious complication of obstructive sleep apnea (OSA) is pulmonary hypertension (PH). Based on previous research that revealed involvement of perivascular immune and inflammatory ...

New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...

As the number of mega-mergers have increased in recent years, and the purchase price of innovative companies rises, it is apparent that many lucrative buyouts fail to meet expectations, although a few ...